CatherineJu-YingWuMD

Oncology • Boston, MA

Hematologic Oncology

Assistant Professor of Medicine, Dana-Farber Cancer Institute

Join to view full profile

Dr. Wu is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Wu's full profile

Already have an account?

Office
450 Brookline Avenue, Dana 520C
Dana Farber Cancer Institute
Boston, MA 02215
Phone+1 617-632-5943

Fax+1 617-632-6380

Education & Training

Brigham and Women's Hospital/Massachusetts General Hospital/Dana-Farber Cancer InstituteFellowship, Hematology and Medical Oncology, 1997 - 2000
Brigham and Women's HospitalResidency, Internal Medicine, 1994 - 1997
Stanford University School of MedicineClass of 1994

Certifications & Licensure

MA State Medical License 1996 - 2025

Awards, Honors, & Recognition

Super Doctor SuperDoctors.com

Clinical Trials

Stem Cell Transplantation After Reduced-Dose Chemotherapy for Patients With Sickle Cell Disease or Thalassemia Start of enrollment: 2001 Sep 01
Terminated
Phase 2
Allogeneic Stem Cell Transplantation Following Chemotherapy in Patients With Hemoglobinopathies Start of enrollment: 2004 Mar 01
Completed
Phase 2
Banking of Chronic Lymphocytic Leukemia Tumor Cells for Vaccine Generation Start of enrollment: 2006 Nov 01
Completed
Phase 1
Reduced Intensity Stem Cell Transplantation for Chronic Lymphocytic Leukemia Followed by Vaccination Start of enrollment: 2007 Feb 01
Completed
Phase 1
Monitoring of Erythroid Lineage Specific Chimerism Following Allogeneic Hematopoietic Transplantation for Thalassemia Major Start of enrollment: 2004 Apr 01
Completed
Join now to see all

Publications & Presentations

PubMed

17 citations
Immune determinants of CAR-T cell expansion in solid tumor patients receiving GD2 CAR-T cell therapy.
Sabina Kaczanowska, Tara Murty, Ahmad Alimadadi, Cristina F Contreras, Caroline Duault
Cancer Cell. 2024-01-08
482 citations
Association of Polymerase e–Mutated and Microsatellite-Instable Endometrial Cancers With Neoantigen Load, Number of Tumor-Infiltrating Lymphocytes, and Expression of P...
Brooke E. Howitt, Sachet A. Shukla, Lynette M. Sholl, Lauren L. Ritterhouse, Jaclyn C Watkins
JAMA Oncology. 2015-12-01
62 citations
Impaired T- and NK-cell reconstitution after haploidentical HCT with posttransplant cyclophosphamide.
Benedetta Rambaldi, Haesook T. Kim, Carol Reynolds, Sharmila Chamling Rai, Yohei Arihara
Blood Advances. 2021-01-26

Journal Articles

A Cloning and Expression System to Probe T Cell Receptor Specificity and Assess Functional Avidity to Neoantigens
William J Lane, Patrick A Ott, Catherine J Wu, Donna E Leet, Blood

Abstracts/Posters

B Cell Restricted Expression of Mutated IKZF3 modulates BCR Signaling and Homing Pathways in a Mouse Model of CLL
Catherine J. Wu, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
Deciphering the Role of Locally Disordered DNA Methylation on CLL Development In Vivo
Catherine J. Wu, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
MCL-1 and PKA/AMPK Axis Fuel Venetoclax Resistance in Lymphoid Cancers
Catherine J. Wu, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
Distinct Evolutionary Patterns in Chronic Lymphocytic Leukemia (CLL) during Resistance to Graft-Versus-Leukemia (GvL)
Catherine J. Wu, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
Interrogation of Individual CLL Loss-of-Function Lesions By CRISPR In Vivo Editing Reveals Common and Unique Pathway Alterations
Catherine J. Wu, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
Spatial Genomic Heterogeneity in Chronic Lymphocytic Leukemia
Catherine J. Wu, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
Clinical and Immunologic Activity of Ipilimumab Following Decitabine Priming in Post-Allogeneic Transplant and Transplant-Na¥ve Patients with Relapsed or Refractory My...
Catherine J. Wu, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
Identification of Genotype-Specific Therapeutic Vulnerabilities By Comparative Dynamic BH3 Profiling Analysis of Human and Murine CLL
Catherine J. Wu, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
Lineage Tracing in Chronic Lymphocytic Leukemia Reveals Clones with Stable Gene Expression States That Differentially Respond to Therapy
Catherine J. Wu, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
T Cell Determinants of Response and Resistance to PD-1 Blockade in RichterÍs Transformation
Catherine J. Wu, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
Join now to see all

Lectures

Genome Editing for Transplantation and Cellular Therapies
61st Annual American Society of Hematology Meeting - Orlando, FL - 12/7/2019
Clonal Dynamics in Chronic Lymphocytic Leukemia
61st Annual American Society of Hematology Meeting - Orlando, FL - 12/7/2019
Response Comes of Age in Chronic Lymphocytic Leukemia
61st Annual American Society of Hematology Meeting - Orlando, FL - 12/7/2019
Continuing Conversations With the Speakers on Genome Editing for Transplantation and Cellular Therapies
61st Annual American Society of Hematology Meeting - Orlando, FL - 12/7/2019
Multimodal Single-Cell Profiling Defines the Epigenetic Determinants of Chronic Lymphocytic Leukemia Evolution
2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
A Clinical Trial of the STAT3 Inhibitor Pyrimethamine in Chronic Lymphocytic Leukemia
2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
Integration of Immunotherapy Into Treatment for Hematologic Malignancies
60th American Society of Hematology Annual Meeting - 11/30/2018
Join now to see all

Press Mentions

Gut Bacteria Engineered to Act as Tumor GPS for ImmunotherapiesOctober 4th, 2024
New Research Offers Hope for Safer and More Effective Blood Stem Cell TransplantsSeptember 4th, 2024
Foundation Stirs Controversy by Charging Cancer Patients $83,000 for Unproven but Promising Experimental DrugMarch 4th, 2023
Join now to see all

Grant Support

Personal Tumor Neoantigens For Immunity Against Chronic Lymphocytic LeukemiaNational Cancer Institute2011–2012
Post-Transplant Vaccines To Enhance Graft-Versus-Leukemia ResponsesNational Heart, Lung, And Blood Institute2010–2011
GM-CSF Secreting Tumor Cell Vaccines To Enhance Post-Transplant Anti-Cll ImmunityNational Cancer Institute2008–2009
GM - CSF - Producing Tumor Cell LINE As A CML VaccineNational Cancer Institute2006
GM-CSF - Producing Tumor Cell LINE As A CML VaccineNational Cancer Institute2005
Leukemia Antigens Following Donor Leukocyte InfusionNational Heart, Lung, And Blood Institute2000–2004